​

Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EW Stock Forecast

Edwards Lifesciences (EW) stock forecast, based on 45 Wall Street analysts, predicts a 12-month average price target of $78.00, with a high of $90.00 and a low of $68.00. This represents a 9.55% increase from the last price of $71.20.

$60 $68 $76 $84 $92 $100 High: $90 Avg: $78 Low: $68 Last Closed Price: $71.2

EW Stock Rating

Edwards Lifesciences stock's rating consensus is Buy, based on 45 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (60.00%), 18 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 45 0 18 27 Strong Sell Sell Hold Buy Strong Buy

EW Price Target Upside V Benchmarks

TypeNameUpside
StockEdwards Lifesciences9.55%
SectorHealthcare Stocks 33.91%
IndustryMedical Device Stocks20.97%

Price Target Trends

1M3M12M
# Anlaysts-126
Avg Price Target-$90.00$79.92
Last Closing Price$71.20$71.20$71.20
Upside/Downside-26.40%12.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25510171-33
Mar, 25410181-33
Feb, 25510171-33
Jan, 25510191-35
Dec, 245919--33
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 29, 2025Rick WiseStifel Nicolaus$90.00$71.1326.53%26.40%
Jan 08, 2025Lee HambrightBernstein$74.00$74.15-0.20%3.93%
Dec 05, 2024Lee HambrightBernstein$72.00$72.63-0.87%1.12%
Dec 05, 2024Richard NewitterTruist Financial$78.00$72.647.38%9.55%
Dec 05, 2024William PlovanicCanaccord Genuity$68.00$73.26-7.18%-4.49%
Oct 30, 2024David RomanGoldman Sachs$80.00$68.6316.57%12.36%
Oct 30, 2024Travis SteedBank of America Securities$75.00$68.639.28%5.34%
Oct 28, 2024Joanne WuenschCitigroup$81.00$69.0517.31%13.76%
Oct 15, 2024David RescottRobert W. Baird$73.00$69.634.84%2.53%
Oct 11, 2024Patrick WoodMorgan Stanley$70.00$68.262.55%-1.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025BernsteinMarket PerformMarket Performhold
Dec 05, 2024BernsteinMarket PerformMarket Performhold
Dec 05, 2024RBC CapitalOutperformOutperformhold
Dec 05, 2024Canaccord GenuityHoldHoldhold
Dec 05, 2024OppenheimerOutperformOutperformhold
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 30, 2024Bank of America SecuritiesNeutralNeutralhold
Oct 28, 2024Cowen & Co.HoldHoldhold
Oct 28, 2024CitigroupBuyBuyhold
Oct 28, 2024BernsteinPerformupgrade

Financial Forecast

EPS Forecast

$1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.32$2.41$2.46$2.31$6.98----
Avg Forecast$1.89$2.26$2.46$2.51$2.57$2.44$2.74$3.11$3.49
High Forecast$2.03$2.43$2.55$2.52$2.60$2.53$2.96$3.40$3.66
Low Forecast$1.78$2.14$2.40$2.48$2.42$2.42$2.41$2.82$3.44
Surprise %-30.16%6.64%--7.97%171.60%----

Revenue Forecast

$4B $5B $6B $7B $8B $9B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.39B$5.23B$5.38B$6.00B$5.44B----
Avg Forecast$4.39B$5.26B$5.37B$5.97B$5.80B$5.82B$6.40B$7.09B$7.77B
High Forecast$4.63B$5.55B$5.52B$6.00B$5.86B$5.86B$6.43B$7.16B$8.07B
Low Forecast$4.20B$5.03B$5.26B$5.94B$5.33B$5.79B$6.37B$7.02B$7.69B
Surprise %0.02%-0.51%0.25%0.59%-6.14%----

Net Income Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$823.40M$1.50B$1.52B$1.40B$4.17B----
Avg Forecast$742.48M$1.39B$1.53B$1.40B$1.57B$1.51B$1.59B$1.89B$2.12B
High Forecast$944.61M$1.67B$1.84B$1.68B$1.58B$1.54B$1.81B$2.07B$2.23B
Low Forecast$540.35M$1.11B$1.22B$1.12B$1.47B$1.48B$1.47B$1.72B$2.09B
Surprise %10.90%8.09%-0.49%-166.36%----

EW Forecast FAQ

Is Edwards Lifesciences stock a buy?

Edwards Lifesciences stock has a consensus rating of Buy, based on 45 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 18 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Edwards Lifesciences is a favorable investment for most analysts.

What is Edwards Lifesciences's price target?

Edwards Lifesciences's price target, set by 45 Wall Street analysts, averages $78 over the next 12 months. The price target range spans from $68 at the low end to $90 at the high end, suggesting a potential 9.55% change from the previous closing price of $71.2.

How does Edwards Lifesciences stock forecast compare to its benchmarks?

Edwards Lifesciences's stock forecast shows a 9.55% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the medical device stocks industry (20.97%).

What is the breakdown of analyst ratings for Edwards Lifesciences over the past three months?

  • April 2025: 15.15% Strong Buy, 30.30% Buy, 51.52% Hold, 3.03% Sell, 0% Strong Sell.
  • March 2025: 12.12% Strong Buy, 30.30% Buy, 54.55% Hold, 3.03% Sell, 0% Strong Sell.
  • February 2025: 15.15% Strong Buy, 30.30% Buy, 51.52% Hold, 3.03% Sell, 0% Strong Sell.

What is Edwards Lifesciences’s EPS forecast?

Edwards Lifesciences's average annual EPS forecast for its fiscal year ending in December 2025 is $2.44, marking a -65.04% decrease from the reported $6.98 in 2024. Estimates for the following years are $2.74 in 2026, $3.11 in 2027, and $3.49 in 2028.

What is Edwards Lifesciences’s revenue forecast?

Edwards Lifesciences's average annual revenue forecast for its fiscal year ending in December 2025 is $5.82B, reflecting a 7.08% increase from the reported $5.44B in 2024. The forecast for 2026 is $6.4B, followed by $7.09B for 2027, and $7.77B for 2028.

What is Edwards Lifesciences’s net income forecast?

Edwards Lifesciences's net income forecast for the fiscal year ending in December 2025 stands at $1.51B, representing a -63.82% decrease from the reported $4.17B in 2024. Projections indicate $1.59B in 2026, $1.89B in 2027, and $2.12B in 2028.